Good MorningStocks got a boost from the Federal Reserve on Wednesday when it released its policy statement. In the
statement, the FOMC says it will aggressively dial back its bond purchasing program because its dual mandate
of employment and inflation have been met. The FOMC is indicating three interest rate hikes by the end of 2022
which is in line with the market’s expectations. The risk now is that inflation won’t respond to the policy shift
and the FOMC will be forced to act even more aggressively than it is now indicating.
On the economic front, the November retail sales figures came in much weaker than expected and reflect the
rising problem of inflation. Retail sales came in at up 0.3% versus an expectation of up 0.5% but the data does
not account for the impacts of inflation. With CPI up 6.8% for the year, the volume of sales is actually down
with the difference in the Retail Sales data made up by higher prices. Featured: 100% overnight gains? (Ad) 
|
Technology | | It was as if equity markets gave a collective sigh of relief yesterday after the Federal Reserve signaled it would begin “aggressive” tapering of its asset purchase program, while also aiming for three interest rate hikes in 2022. The uncertainty around just how the Fed would react to ri... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Markets | | Personal financial management platform provider MoneyLion (NYSE: ML) stock has lost nearly (-70%) of its value from its 2021 peak. The fintech envisions building a digital private banks for the working middle class and focuses on marketing heavily to the Generation-Z demographic. With an easy to use... Read the Full Story |
|
Markets | |
Like a missing dog, meme stocks have been lost but not forgotten in recent months. The collection of oft irrationally charged tickers have largely fallen out of favor in the market with most traders having (for now) moved on the next big thing. For a novelty act that loudly dominated the headlines... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Communication Services | |
Time to Buy the Dip in Quality Tech Companies?
Investors have been dealing with a volatile stretch in the market during the past few weeks, especially in the tech sector. Many of the big winners from earlier in the year are well off of their 52-week highs and continue to face selling pressure on ... Read the Full Story |
|
Industrials | |
ABM Plunges On Unexpected Spending Plans
Shares of ABM Industries, Incorporated (NYSE: ABM) are down nearly 10% in the wake of the Q4 earnings report and there are more reasons than one. Ultimately, the news is good but was not well received by the market. The Q4 results themselves were fine, it ... Read the Full Story |
|
From Our Partners | | A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar.
It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm.
A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story. | | Click here for instant access to the free report now |
|
Technology | |
The unlikely meme stock is showing investors its business strategy is starting to pay off
BlackBerry (NYSE:BB) was one of the stranger companies to be part of the meme stock movement. The company is best known for its namesake mobile devices. Nevertheless, the low share price at the beginning of... Read the Full Story |
|
Consumer Discretionary | |
Blue Chip McDonald’s Still Winning The Burger Wars
After checking the latest happenings in the burger world two things have become clear. The burger and, in particular the QSR burger, the industry is doing just fine and within that McDonald’s (NYSE: MCD) stands out as the clear winne... Read the Full Story |
|
Industrials | |
There Are Reasons To Be Wary Of FedEx FQ2 Results
If you are thinking FedEx (NYSE: FDX) is going to have a strong quarter you are probably right. The company is forecasting a 10% increase in holiday deliveries that, when coupled with all the price increases, should deliver revenue growth in the ... Read the Full Story |
|
Markets | | Premium retail department store chain Nordstrom (NYSE: JWN) stock was crippled on its Q3 2021 results and forward guidance ahead of the holiday shopping season. Nordstrom Rack has been the weak spot for the retailer as it continued to face inventory issues due to supply chain constraints. The Compan... Read the Full Story |
|
Industrials | |
REV Group Slips On Supply Chain Issues
REV Group (NYSE: REVG) stock popped earlier this year on rising demand for its products across all lines. The demand led the company to raise guidance, outperform expectations, resume the dividend, and send shares to the highest levels in three years. Now, ... Read the Full Story |
|
The Early Bird Stock Of The Day Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. | | View Today's Stock Pick |
|
